In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
LY2784544 is a potent, selective inhibitor of JAK2 with IC50 value of 3 nM.
Janus kinase 2 (JAK2) belongs to the Janus kinase family and is a member of the type II cytokine receptor family. It is a non-receptor tyrosine kinase. The JAK2 mutation (V617F) within the autoinhibitory pseudokinase domain results in a gain-of-function activation of JAK2.The JAK2V617F mutant results in subsequent phosphorylation of signal transducer and activator of transcription 5 (STAT5). Then, STAT5 regulates the transcription of genes associated with cell growth, death and differentiation. The JAK2V617F mutant is oncogenic in cells, and sufficient for generating the myeloproliferative neoplasms (MPN) phenotypes in murine models. Mutant JAK2 kinase is an attractive therapeutic target for the therapy of MPNs. To selectively inhibit JAK2V617F but minimizing inhibition of wild-type JAK2 would be an optimal treatment approach.
LY2784544 is a potent and ATP-competitive inhibitor of JAK2 tyrosine kinase. LY2784544 has 8- and 16-fold selectivity for JAK2 than JAK1 and JAK3, respectively. LY2784544 more effective on inhibiting the phosphorylation of STAT5 in Ba/F3-TEL-JAK2 cells than in Ba/F3-TEL- JAK3 and –JAK1 cells with IC 50 of 0.191 (JAK2), 2.904 (JAK1) and 4.744 nM (JAK3). LY2784544 significantly inhibited STAT5 phosphorylation at a concentration range from 50 nM–20 nM in Ba/F3 cells expressing JAK2V617F. On the other hand, LY2784544 showed minimal inhibition of STAT5 phosphorylation at 50 and 200 nM concentrations in IL-3-stimulated Ba/F3 cells which express wild-type JAK2. LY2784544 significantly inhibited the cell proliferation of JAK2V617F-expressing cells with IC50 ＝55 nM. In JAK2V617F-expressing cells, LY2784544 induced apoptosis with EC50±s.d.of 113±0.023 nM measured by Caspase3/7-glo assays.
LY2784544 with a TED50 (threshold effective Dose 50) of 12.7 mg/kg, potently inhibits STAT5 phosphorylation in SCID mice bearing Ba/F3-JAK2V617F-GFP. In mouse hematologic disease model, LY2784544 also dose-dependly reduces Ba/F3-JAK2V617F-GFP tumor burden.
1.Ma L, Clayton JR, Walgren RA, Zhao B, Evans RJ, Smith MC, Heinz-Taheny KM, Kreklau EL, Bloem L, Pitou C et al: Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J 2013, 3:e109.
|Physical Appearance||A solid|
|Storage||Store at -20°C|
|Solubility||≥23.5 mg/mL in DMSO, ≥5.65 mg/mL in EtOH with ultrasonic and warming,insoluble in H2O|
|Shipping Condition||Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Description||LY2784544 is a highly potent and selective inhibitor of wild-type JAK2 and V617F mutant JAK2 with IC50 values of 2.26 μM and 55 nM, respectively.|
|Targets||wild-type JAK2||V617F mutant JAK2|
|IC50||2.26 μM||55 nM|